Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience - 12/08/23
, Ilaria Iorillo a, 1 , Vitaliano Nicola Quaranta b , Leonardo Maselli a , Ernesto Lulaj a , Enrico Buonamico a , Silvano Dragonieri a, ⁎ , Giovanna Elisiana Carpagnano a Abstract |
Introduction |
Dupilumab, a fully human anti-interleukin-4/interleukin-13 monoclonal antibody, has shown efficacy in many aspects of Type-2 severe asthma management. Currently, we lack real-life studies addressing the achievment of clinical remission in patients treated with this biologic.
Materials and methods |
We performed a prospective study enrolling 18 patients with severe asthma treated with Dupilumab. We assessed main clinical, functional and biological severe asthma features at baseline (T0) and after a 1-year course of treatment (T12). Clinical remission was defined at T12 in patients without asthma exacerbations, no oral corticosteroid (OCS) use, ACT ≥ 20 and FEV1 improvement ≥ 100 ml from baseline.
Results |
Among total population, 38.9% of patients achieved clinical remission at T12. Anti IL-4/IL-13 treatment significantly reduced asthma exacerbations and OCS use in the overall cohort, with a more pronounced ACT improvement in the remission group. Patients achieving clinical remission went through a step down of the inhalation therapy, suspending long-acting anti-muscarinics administration at T12.
Conclusions |
Treatment with anti-IL4/IL13 can induce clinical remission in patients with T2 severe asthma.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Dupilumab can induce severe asthma clinical remission in real life assessments. |
• | Remittent patients showed higher baseline and T12 blood eosinophilic count. |
• | Patients achieving clinical remission could decrease inhalation therapy. |
Keywords : Severe asthma, Remission, Dupilumab, Eosinophil, FeNO
Abbreviations : ACT, CRSwNP, DMARD, ICS, EGPA, OCS, LABA, IL-4, IL-13, TAI, SD, IQR, FeNO
Plan
Vol 217
Article 107348- octobre 2023 Retour au numéro
Article précédent
- Bronchial thermoplasty attenuates bronchodilator responsiveness
- Cyndi Henry, Sabrina Biardel, Magali Boucher, Krystelle Godbout, Jamila Chakir, Andréanne Côté, Michel Laviolette, Ynuk Bossé
- Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study
- Konstantinos Kostikas, Jorge F. Maspero, Kenneth R. Chapman, Karen Mezzi, Xavier Jaumont, David Lawrence, Richard van Zyl-Smit
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?